Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.67 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-08-23Read Distribution5.49-33.2% to today ✓Markdown gives way to Distribution
2026-07-02Read Markdown5.62-34.7% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
BrightSpire Capital Inc holds its Distribution at $3.67. Consolidating, no directional conviction, held for 344 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 344 days
Price at the screen
$3.67
Valuation
N/A trailing · 6.02 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.36
The Workings
Five Screens, Shown in Full
Does not pass. Business activity: conventional financial services
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Its core business involves an activity the values screen does not clear.
Fail
Debt load
69.87%
Below 33%
Interest-bearing debt is 69.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
3.15%
Below 49%
Money owed to the company is 3.2% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
BrightSpire Capital does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BRSP's ethical verdict changes
Today BRSP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.01x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BRSP trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Distribution$3.79+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$3.79+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$3.79+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$3.79+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$3.79+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$3.79+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$3.79+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Distribution$3.79-0.5%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Distribution$3.81-8.9%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6.
2026-10-02Distribution$4.18-23.9%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 23.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (8 analysts) rates it buy, with a mean price target of $6. Since the last review it its composite score rose.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.